While the molecular mechanism accounting for this selectivity remains to be fully elucidated, it is plausible that the downregulation of KRAS expression by let-7b is dependent on the stoichiometry between KRAS mRNA and let-7b in tumor cells. The gene discussed is KRAS; the disease is neoplasm.